SHTG advice statements

SHTG advice statements

SHTG Advice Statements outline in as consistent a manner as possible the view of the SHTG on the clinical effectiveness, safety and cost effectiveness evidence for the technology in question in the context of NHSScotland.

The status of SHTG Advice Statements for NHSScotland is ‘required to consider’. They are intended to assist NHS planners and decision makers when determining the place of health technologies for local use. It is acknowledged that the evidence constitutes only one of the sources needed for decision making and planning in NHSScotland. SHTG advice does not override the individual responsibility of health professionals to make decisions in the exercise of the clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Share this content

Published Date: default

Evidence

Latest SHTG publications

  • What is the clinical effectiveness, cost effectiveness and safety of home health monitoring compared with usual care for patients with moderate to severe chronic obstructive pulmonary disease?
    Evidence note
    Advice Statement
  • What is the clinical effectiveness and cost effectiveness of home health monitoring devices compared with usual care for patients with hypertension?
    Evidence note
    Advice Statement
  • What is the effectiveness, safety and cost-effectiveness of the MitraClip® transcatheter mitral valve repair system in patients with moderate to severe or severe mitral regurgitation who are at high surgical risk or are non-surgical candidates?            
    Evidence note
    Advice Statement
  • Is patient self-monitoring (including self-testing and self-management) of oral anticoagulation therapy safe, efficacious and cost effective?
    Evidence note

    Advice Statement